Navigation Links
Alternative to the Conventional Seizure Treatment

Researchers at the David Geffen School of Medicine, University of California, Los Angels and Valencia, Calif.-based Advanced Bionics Corp., trigeminal nerve// stimulation (TNS) have developed an alternative to the conventional epilepsy treatment.

It is a nerve-stimulation treatment where in the study and the clinical trails show that it has the potential to control seizures. I this treatment the nerve that prevents seizures is stimulated to inhibit epilepsy. This new treatment is much more effective than those that can be acquired by seizure medication and surgery. The trigeminal nerve extends into the brain from the face and forehead, and is known to play a role in seizure inhibition. The stimulator and electrodes used to transmit an electrical current to the nerve can be worn externally or implanted.

A study published in the July edition of the peer-reviewed journal Epilepsia reports that four of seven subjects who used an external stimulator for at least three months in a pilot human clinical trial enjoyed a 50 percent or better reduction in seizure frequency. ‘Most people with chronic epilepsy who have continuing seizures are drug-resistant,’ said Dr. Christopher DeGiorgio, vice chair and professor in residence of neurology at UCLA, and co-developer of TNS and lead author of the study.

In addition, anti-seizure drugs can have significant side effects on behavior, thinking and alertness. Women taking anti-seizure drugs and their unborn children are at special risk because of the effect of these drugs on fetal growth and development. ‘For all of these reasons, we need to find non-drug alternative treatments,’ DeGiorgio said. ‘The results of our pilot study support further investigation into the safety and efficacy of TNS for epilepsy.’ Forty percent of the 2.5 million people in the United States with epilepsy have poorly controlled seizures. Recurrent seizures lead to social isolation, unemployment, inability to drive and injuries fro m falls and burns, as well as drowning. Approved treatment options include a variety of medications, neurosurgery that involves removing a small portion of the brain responsible for the seizures, and vagus nerve stimulation (VNS).

Despite the introduction of multiple new antiepileptic drugs since the 1990s, as many as one million individuals with epilepsy across the country fail to benefit from drug treatment. While surgery can be effective, many patients are either not ideal candidates or lack access to one of the few specialized epilepsy centers, such as UCLA, where surgery is offered. VNS treatment has helped thousands who could not control their seizures with medication and were ineligible for surgery. TNS, however, holds several potential advantages over VNS, DeGiorgio said. Unlike VNS, the TNS stimulator can be tested externally to gauge results before implanting the device. Patients treated in the clinical trial wore the stimulator on their belt. Wires from the stimulator were passed under clothing and connected to electrodes attached to the face by adhesive. The electrodes could be covered by a cap or hat. In addition, while VNS stimulates only one side of the brain, TNS stimulates both sides, a theoretical advantage that will require more testing to validate and quantify. The cost of an external TNS stimulator is about $180. The monthly retail cost of batteries and electrodes is $150 to $170.

Source Eurekaert
'"/>




Related medicine news :

1. Prince Charles lends support to Alternative Medicine
2. Alternative medicine more popular among HIV positive patients
3. Complementary and Alternative medicine
4. Alternative therapies popular with Parkinsons patients
5. Alternative to blood Transfusions
6. Alternative Therapy in HIV Patients
7. An Alternative to Warfarin
8. Another Alternative For Diabetics On Insulin
9. The Use Of Alternative Medicine On The Rise
10. Heart Patients Use Alternative Medicine
11. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: